Correlation Between Incyte and Lipella Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Incyte and Lipella Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Incyte and Lipella Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Incyte and Lipella Pharmaceuticals Common, you can compare the effects of market volatilities on Incyte and Lipella Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Incyte with a short position of Lipella Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Incyte and Lipella Pharmaceuticals.

Diversification Opportunities for Incyte and Lipella Pharmaceuticals

-0.49

Correlation Coefficient

Incyte  Lipella Pharmaceuticals

Very good diversification

The 3 months correlation between Incyte and Lipella is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Incyte and Lipella Pharmaceuticals Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipella Pharmaceuticals and Incyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Incyte are associated (or correlated) with Lipella Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipella Pharmaceuticals has no effect on the direction of Incyte i.e., Incyte and Lipella Pharmaceuticals go up and down completely randomly.

Pair Corralation between Incyte and Lipella Pharmaceuticals

Given the investment horizon of 90 days Incyte is expected to generate 4.22 times less return on investment than Lipella Pharmaceuticals. But when comparing it to its historical volatility, Incyte is 4.33 times less risky than Lipella Pharmaceuticals. It trades about 0.07 of its potential returns per unit of risk. Lipella Pharmaceuticals Common is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  303.00  in Lipella Pharmaceuticals Common on October 10, 2024 and sell it today you would earn a total of  15.00  from holding Lipella Pharmaceuticals Common or generate 4.95% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Incyte  vs.  Lipella Pharmaceuticals Common

Incyte

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Incyte are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Incyte showed solid returns over the last few months and may actually be approaching a breakup point.

Lipella Pharmaceuticals

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Incyte and Lipella Pharmaceuticals

The main advantage of trading using opposite Incyte and Lipella Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Incyte position performs unexpectedly, Lipella Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will offset losses from the drop in Lipella Pharmaceuticals' long position.

The idea behind Incyte and Lipella Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .